CASODEX NEWS HIGHLIGHTS
Media Articles Related to Casodex (Bicalutamide)
Height Linked To Risk Of Prostate Cancer Development And Progression Source: Cancer / Oncology News From Medical News Today [2008.09.04]
Too Much Calcium In Blood May Increase Risk Of Fatal Prostate Cancer Source: Clinical Trials / Drug Trials News From Medical News Today [2008.09.04]
Study Links Serum Calcium, Prostate Cancer Death Source: MedicineNet Cancer Specialty [2008.09.04]
ProsCan For Men: Randomised Controlled Trial Of A Decision Support Intervention For Men With Localised Prostate Cancer Source: Cancer / Oncology News From Medical News Today [2008.09.03]
Scientists Find Second Site For Prostate Cancer Gene Source: Genetics News From Medical News Today [2008.09.03]
Published Studies Related to Casodex (Bicalutamide)
Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. [2007.10]
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. [2007]
Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. [2007]
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. [2006.09]
Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. [2006.07]
Clinical Trials Related to Casodex (Bicalutamide)
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX [Completed]
Casodex - Nolvadex Combination [Completed]
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer [No longer available]
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer [Active, not recruiting]
Phase II Trial: Higher Dose Casodex in Hormone Refractory Prostate Cancer Patients. [Recruiting]
|